Morgan Stanley analyst Terence Flynn maintains $AbbVie (ABBV.US)$ with a buy rating, and maintains the target price at $231.
According to TipRanks data, the analyst has a success rate of 54.7% and a total average return of 8.3% over the past year.
Furthermore, according to the comprehensive report, the opinions of $AbbVie (ABBV.US)$'s main analysts recently are as follows:
AbbVie reported a solid third quarter. However, the success of Emraclidine appears to be already factored into the current valuation, according to an analyst.
The firm is revising its projections after assessing AbbVie's third-quarter financial performance, noting that the company delivered a strong quarter, surpassing expectations with its sales and quarterly earnings per share.
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
